LIVE — Last crawled: 2026-11-14 07:06 JST
Vol.1 — November 15, 2026
MSC Portal ›Regulatory Watch› All Entries (76)
Standards, Guidance & Notices
Showing 11–20 of 76
EU
MDCG
Borderline Background Note
Background note on the use of the Manual on borderline and classification for medical devices under the Directives
PUBLISHED SaMD Classification & Approval
Background note explaining that the manual on borderline and classification issued in May 2019 under the old medical device Directives (such as 93/42/EEC) remains available as a reference resource even after the new manual under the MDR (Regulation (EU) 2017/745) and IVDR (Regulation (EU) 2017/746) became operative in September 2022. It applies for as long as devices CE-marked under the old Directives remain on the market, and is maintained by the Borderline and Classification Working Group (BCWG) under the MDCG. It is non-binding guidance.
Published: 2026-04-01
EU
MDCG
MDCG 2021-24 Rev.1
Guidance on classification of medical devices
PUBLISHED SaMD Classification & Approval
Revision 1 of MDCG 2021-24 (guidance on classification of medical devices under the EU MDR), published 20 April 2026. It clarifies terminology by replacing the word "surgical" with "clinical" in the invasiveness definition, and updates the tables and practical notes for Classification Rules 2, 8, 9, 10, 12, 16 and 22. Based on the sources reviewed, the software classification rule (Rule 11) itself was not amended in this revision.
Published: 2026-04-01
FDA
CDRH
fda_20260327_patient_preference_tplc
FDA Issues Final Guidance on Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle
FINAL SaMD Classification & Approval
FDA CDRH issued final guidance on the collection and submission of patient preference information (PPI). It includes recommendations on study design, validation, and the integration of PPI across the total product life cycle, and provides a roadmap for sponsors incorporating the patient perspective into regulatory submissions.
Published: 2026-03-27
MHLW
Notice
Admin-Notice-2026-03-25_SaMDQA3
Q&A Regarding Handling of Medical Device Software (Part 3) (Administrative Notice, March 25, 2026)
NEW SaMD Classification & Approval
Q&A (Part 3) issued by the Japanese Ministry of Health, Labour and Welfare (MHLW), clarifying when manufacturing/marketing and sales activities are deemed to begin for home-use medical device software (SaMD) distributed via app stores or download servers. Manufacturing/marketing is deemed to start when the software is made available on a download server or app store, while sales is deemed to start when the end user is able to use it. Issued 25 March 2026 in response to a growing number of approved home-use device programs. It also confirms that a company acting as both marketing authorization holder and seller needs both business licenses (or notifications), and that legally required labeling information may be provided via easily accessible electronic records rather than a printed insert, provided it is given to the user before use.
Published: 2026-03-26
MHLW
Notice
Admin-Notice-2026-03-19_VPNSecurity
Notice on Strengthening Cybersecurity Measures for Network Devices such as VPN Equipment Connected to Medical Devices (Caution Alert) (Administrative Notice, March 19, 2026)
NEW Cybersecurity
Caution alert (administrative notice, 19 March 2026) issued by the Japanese Ministry of Health, Labour and Welfare (MHLW) in response to a rise in ransomware attacks that exploit VPN equipment and other network devices connected to medical devices. It calls on marketing authorization holders to (1) confirm, under maintenance contracts with healthcare facilities, who is responsible for managing attached network equipment such as VPN devices, (2) check that firmware is up to date and identify any devices that are no longer supported, and (3) strengthen security by informing facilities about unsupported devices and applying stronger authentication and access control.
Published: 2026-03-25
MHLW
Notice
MHLW-PFSB-MDED-0306-No.1
Notice MHLW-PFSB-MDED-0306-No.1 on Handling of Registration Applications for Registered Conformity Assessment Bodies (March 6, 2026)
NEW SaMD Classification & Approval
Notice (MHLW-PFSB-MDED-0306-No.1, 6 March 2026) issued by the Medical Device Evaluation Division setting out procedures for the registration and operation of Registered Conformity Assessment Bodies (RCABs) for medical devices and in vitro diagnostics in Japan. It principally implements a new succession-of-status scheme introduced by the 2025 amendment to the PMD Act (Act No. 37 of 2025), covering business transfers, inheritance, mergers, and demergers of RCABs. The notice also covers registration application procedures and the registration license tax (JPY 90,000), notification requirements for suspension or discontinuation of business (at least two weeks before the planned date), operating rules aligned with ISO/IEC 17021-1 and 17065, restrictions on consulting activities that could compromise confidentiality or impartiality, and detailed succession procedures beginning with prior consultation six months in advance. The notice takes effect on 1 May 2026.
Published: 2026-03-06
MHLW
Notice
MHLW-PFSB-MDED-0306-No.4
Notice MHLW-PFSB-MDED-0306-No.4 on Establishment of Witness Inspection Implementation Standards for Registered Conformity Assessment Bodies and Partial Revision of On-site Inspection Standards (March 6, 2026)
NEW SaMD Classification & Approval
Notice (MHLW-PFSB-MDED-0306-No.4, 6 March 2026) establishing implementation standards for a new witness inspection scheme for Registered Conformity Assessment Bodies (RCABs) and partially revising the existing on-site inspection standards. The witness inspection scheme, introduced under the 2025 amendment to the PMD Act (Act No. 37 of 2025), aims to maintain and standardize the assessment capabilities of RCABs. Under it, MHLW and PMDA staff observe an RCAB conformity assessment roughly once a year, with at least two officials attending and with the consent of the assessed facility, carried out in a manner intended not to affect the assessment itself. The revised on-site inspection standards separate out the witness inspection procedure and newly require RCABs to make efforts so that the assessed facility understands and agrees to accept a witness inspection. The notice takes effect on 1 May 2026.
Published: 2026-03-06
MHLW
Notice
MHLW-PSEHB-PSD-0210-No.3
Notice on Partial Revision of 'Reporting of Medical Device Defects and Other Incidents' (Notice MHLW-PSEHB-PSD-0210-No.3, February 10, 2026)
NEW Post-Market Surveillance
Notice (MHLW-PSEHB-PSD-0210-No.3, 10 February 2026) partially revising the attachment to the 2020 notice on Reporting of Medical Device Defects and Other Incidents (No. 0131-1, 31 January 2020). Issued in connection with the 2025 amendment to the PMD Act (Act No. 37 of 2025) and the related 2025 ministerial ordinance (Ordinance No. 117 of 2025), the revision removes known deaths or serious cases involving foreign medical devices and foreign regenerative medicine products from the scope of the 30-day reporting requirement, while newly requiring 15-day reporting for defects in such foreign products that are not readily foreseeable, whose occurrence trend is unclear, or that suggest a risk of harm to public health and hygiene, along with other technical revisions. The notice takes effect on 1 May 2026.
Published: 2026-02-13
FDA
CDRH
FDA-2026-D-Cybersecurity-QMS
Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
FINAL Cybersecurity
Under Section 524B of the FD&C Act, added by the 2023 Consolidated Appropriations Act, this guidance requires SBOM submission, a vulnerability disclosure process, and coordinated vulnerability disclosure (CVD) planning as part of premarket review. The title change from "Quality System" to "Quality Management System" reflects FDA's move from the legacy QSR to the ISO 13485-based QMSR. IEC 81001-5-1 and AAMI TIR57 appear as two of several optional frameworks manufacturers may draw on for secure product development — alongside JSP2 and ISA/IEC 62443-4-1 — rather than as standards the guidance formally aligns with.
Published: 2026-02-03
FDA
CDRH
FDA-2022-D-0795
Computer Software Assurance for Production and Quality Management System Software
FINAL Quality Management
FDA final guidance (Feb 2026) on risk-based assurance for software used in medical device production and quality management systems. Supersedes the September 24, 2025 version, with the title updated from "Quality System Software" to "Quality Management System Software" to align with the QMSR (21 CFR Part 820 / ISO 13485:2016 harmonization effective February 2, 2026). Replaces Section 6 of the 2002 GPSV. Does NOT apply to SaMD/SiMD.
Published: 2026-02-03
‹ 1 2 3 4 … 8 ›